EP0514506B1 - Lipid formulation system - Google Patents

Lipid formulation system Download PDF

Info

Publication number
EP0514506B1
EP0514506B1 EP91919389A EP91919389A EP0514506B1 EP 0514506 B1 EP0514506 B1 EP 0514506B1 EP 91919389 A EP91919389 A EP 91919389A EP 91919389 A EP91919389 A EP 91919389A EP 0514506 B1 EP0514506 B1 EP 0514506B1
Authority
EP
European Patent Office
Prior art keywords
lipid
particle forming
forming matrix
matrix according
lipid particle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP91919389A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0514506A1 (en
Inventor
Bengt Herslöf
Martin Nicklasson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Pharmacia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia AB filed Critical Pharmacia AB
Publication of EP0514506A1 publication Critical patent/EP0514506A1/en
Application granted granted Critical
Publication of EP0514506B1 publication Critical patent/EP0514506B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A61K8/553—Phospholipids, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the present invention relates to lipid matrices which provide the release of bioactive agents through the formation of a type of liposomes in vivo when the matrices interact with water.
  • the spherical lipid bilayers thus formed in vivo hereinafter referred to as Biosomes (or lipid particle) and the lipid matrix, referred to as a Biosome Forming Matrix (BFM)
  • BFM Biosome Forming Matrix
  • the invention also relates to the production and use of these lipid matrices (BFM).
  • Parenteral depot systems are widely known to those skilled in the art and are well accepted concepts for long term delivery of drugs. These systems are based on biodegradable polymer systems or lipid formulations, e.g. oil solutions and oil suspensions. However, both systems show a serious disadvantage since, after the drug release process has terminated, the lipids or polymer carriers are still at the injection site for a long period of time and, for some systems such as implants, they may even have to be eliminated by surgery. Furthermore, the application of either oils or biodegradable polymers such as polylactic/polyglycolic acid show limited applications since each concept requires specific physicochemical properties of the bioactive material to be included into the systems, e.g. solubility or stability/compatibility.
  • parenteral therapy needs a delivery system for bioactive materials applicable for both highly polar as well as nonpolar bioactive materials for which the delivery system shows an intrinsic rate controlling mechanism for drug release, which can be varied over an extensive time frame.
  • a characteristic for such delivery system should be that both the drug release and the biodegradation occur simultaneously.
  • the adsorption through biological membranes is a very complex process due to the varying nature of the different membranes to be bypassed as well as the varying nature of the bioactive material used.
  • Many enterally administered drugs also show a high biotransformation when absorbed from the gastrointestinal tract or show a restricted or erratic absorption capacity due to their physicochemical properties, molecular size or sensitivity to degradation processes in the gut, or due to some specific absorption mechanism in limited parts of the gastrointestinal tract.
  • bioactive material administered intranasally or dermally may show erratic and irregular absorption and many delivery formulations hence need the addition of absorption enhancers which in some cases have been shown to be detrimental to the nasal mucosa or the skin due to local side effects.
  • the enteral/nasal/dermal therapy needs a delivery system which eliminates this variability and which is sufficiently flexible for incorporating a variety of bioactive materials, independent of their physicochemical properties, molecular size or source of origin, particularly for such bioactive materials which currently cannot be administered via the enteral route due to limited absorption capacity.
  • bioactive materials there is a therapeutic need to administer bioactive materials locally, such as in wounds after surgery or for the treatment of burns.
  • local application to other regions in the body, such as in the vagina, with an extended drug delivery may show therapeutic advantages.
  • a liposome is defined as a structure consisting of one or more concentric spheres of lipid bilayers separated by water or aqueous buffer compartments.
  • Liposomes can be prepared by different methods using solvents, reduced pressure, two-phase systems, freeze drying, sonication etc. (Weiner et al., Drug Dev. Ind. Pharm. 1989 , 15 , 1523). The process technology assigned to these methods is highly complicated. Due to the specific demand in terms of the physicochemical properties of the drug molecule in order to form stable liposome structures, only a limited number of candidate drugs have been shown to be applicable in liposomes formed in vitro .
  • liposomes have so far been restricted to parenteral delivery and for cosmetic skin care products even though attempts have been made for other routes of administration such as oral, nasal, pulmonary.
  • the applications for parenteral use have been focused on intravenous administration and drug targeting and to some minor extent for extended or controlled release from a depot.
  • the applications of liposomes are restricted to the formation and incorporation of bioactive materials in vitro .
  • a composition for oral delivery of drugs has been disclosed in a patent by Yesair (WO 86/05694), comprising non-esterified fatty acids, monoglycerides with fatty acids having 14-18 carbon atoms, lysophosphatidylcholine in which the fatty acid component has 14-18 carbon atoms and a drug. None of these single-chained components are bilayer-forming which is a prerequisite for at least one of the lipid components in the present invention.
  • EP 158 441 discloses a dry lipid-based solid material which forms or reconstitutes liposomes in the presence of water. This composition should be dehydrated, e.g. through lyophilization or spray-drying which should not destroy the liposome structure.
  • water-miscible liquid e.g. glycerol, ethanol
  • membrane lipid e.g. phospholipids such as soy lecithin and egg yolk lecithin.
  • EP 260 241 discloses a dry lipid-based solid material which forms or reconstitutes liposomes in the presence of water. This composition should be dehydrated, e.g. through lyophilization or spray-drying which should not destroy the liposome structure.
  • WO 87/07502 discloses a pro-liposome formulation comprising of at least one volatile liquid propellant and at least one lipid component. Also in this case discrete particles are formed by dehydration and thus the liposomes are present from the beginning.
  • the above mentioned problems and needs can be met by using a delivery system as described in this application.
  • the present invention relating to Biosome formation in vivo , will show advantages as compared to already well known lipid drug delivery systems.
  • the present invention discloses a way to produce, use and/or utilize an entrapment or adsorption procedure for bioactive substances into unique lipid matrices.
  • Such a combination may be used as a pharmaceutical formulation within human and veterinary medicine, in agriculture, or as cosmetic or food/nutritional formulations.
  • a lipid particle forming matrix is characterized by that from a system of at least two defined lipid components chosen from classes of different polarity, in which at least one of the lipid components is bilayer forming, discrete lipid particles are formed spontaneously when interacting with excess aqueous systems.
  • a defined lipid component is a lipid whose chemical composition is known and controlled. In the system at least one of the lipid components is amphiphatic and polar and one is nonpolar.
  • the amphiphatic and polar component is preferably phosphatidylcholine and the nonpolar lipid is preferably chosen from the classes of mono-, di- and triglycerides or a mixture thereof.
  • the lipid particle forming matrix has a liquid or semi-solid consistency.
  • the amount of the polar lipid class components should be in the range of 5-80 % (w/w) of the lipid system, preferably in the range of 10-60 % (w/w).
  • the amount of the polar and amphiphatic lipid class components should be in the range of 5-80 % (w/w) of the lipid system, preferably in the range of 25-50 % (w/w).
  • the lipid particle forming matrix contains bioactive materials, which could be chosen from the groups of drugs, herbicides, pesticides, fertilizers, food and cosmetic ingredients or additives.
  • bioactive materials which could be chosen from the groups of drugs, herbicides, pesticides, fertilizers, food and cosmetic ingredients or additives.
  • the amount of bioactive material is below 70 % (w/w) of the matrix, preferably below 50 % (w/w).
  • the discrete particles are formed spontaneously from the matrix without any chemical or physical treatment or initiation.
  • the amphiphatic and polar or the nonpolar lipid is mixed with the bioactive material per se , or in solution, and preferably the nonpolar lipid or lipids are admixed to the mixture of the bioactive material and the amphiphatic and polar lipid or lipids.
  • the lipid particle forming matrix could be used as a carrier system for bioactive materials and especially in pharmaceutical compositions such as oral, rectal, nasal, vaginal, ocular or parenteral vehicles, creams, ointments, capsules and tablets and they could be used for the manufacturing of a pharmaceutical composition for enteral, parenteral, nasal, intravaginal, ocular administration or administration locally on skin, wounds or mucous membranes.
  • pharmaceutical compositions such as oral, rectal, nasal, vaginal, ocular or parenteral vehicles, creams, ointments, capsules and tablets and they could be used for the manufacturing of a pharmaceutical composition for enteral, parenteral, nasal, intravaginal, ocular administration or administration locally on skin, wounds or mucous membranes.
  • the property 'bilayer forming' is a well-known physical parameter and can easily be established by suitable physicochemical methods (e.g. surface balance method).
  • suitable physicochemical methods e.g. surface balance method.
  • the establishment of the formed discrete lipid particles can be done by physical and/or chemical methods, such as microscopy using polarized light, or diffraction methods.
  • the present invention relates to bioactive materials to be entrapped in lipid matrices and will not be restricted to any particular class of bioactive material in terms of physicochemical properties, molecular size or the source of origin, i.e. synthetic, biotechnological materials, etc.
  • the variation in the lipid composition provides the control mechanism by which Biosomes are formed and thereby to the rate of Biosome formation which will serve as a controlling factor for either immediate or sustained release of the entrapped or associated bioactive materials.
  • the matrix of the invention can only be defined in general terms as given in Claim 1.
  • the system according to the invention can be obtained.
  • a bioactive material within the scope of the present invention, is defined in its broadest sense, such as a biologically active substance having effect and/or is used within human and/or veterinary medicine, cosmetics as well as within agricultural areas (pesticides, herbicides and/or fertilizers). Also included are areas such as food.
  • bioactive agent Any type of bioactive agent can be applied.
  • this invention is focused on the principle of lipid particle forming matrices which may contain a bioactive agent where said bioactive agent and hence the Biosome forming matrix design are based upon the physicochemical properties of the various matrix components.
  • a pharmacologically active substance a salt, solvate, enantiomer, or a polymorph thereof may be used, including substances that are synthetic or biosynthetic in their origin.
  • substances that are used as herbicides or substances that act as stimulators on crop may be used.
  • substances that have an effect on various parasites are included.
  • the invention may be used to incorporate additives, such as vitamins, preservatives, spices or other taste-carriers in order to protect and/or release such substances in connection with consumption or storage of food.
  • lipids - a general term for natural or synthetic compounds consisting of acyl carriers, such as glycerol, sphingosine, cholesterol, and others or derivatives thereof, to which one or more fatty acids are or could be linked. Also similar molecules that contains a substantial hydrocarbon portion may be included.
  • the lipids used for the Biosome Forming Matrices can be classified into different lipid classes depending on their polarity, namely: nonpolar lipid classes - these have no polar head groups.
  • nonpolar constituents are hydrocarbons, or non-swelling amphiphiles, such as mono-, di- and triacylglycerols, cholesterol, fatty alcohols or cholesterol esters.
  • polar lipid classes - these have polar head groups and possess surface activity, such as phospholipids or glycolipids. Depending on their specific interactions with water they are further subdivided into the categories of swelling and soluble amphiphiles.
  • amphiphatic or amphiphilic lipid classes such as phospholipids and glycolipids, being surface active.
  • bilayer forming lipid classes - amphiphatic lipids such as PC (phosphatidylcholine), sphingomyelin, Pl (phosphatidylinositol), with a molecular geometry that preferentially leads to bilayer structures in the presence of water.
  • PC phosphatidylcholine
  • Pl phosphatidylinositol
  • the lipids used for the BFM consist of a mixture of lipid classes characterized by their different polarities.
  • Polar lipids such as phospholipids or glycolipids
  • nonpolar lipids such as mono-, di- and triglycerides
  • sterols such as cholesterol, fatty acids, fatty alcohols and esters thereof as well as other lipid classes may be utilized.
  • This well defined mixture of lipids from different classes as defined above should not be confused with commercial products such as soybean oil, maize oil or soy lecithin and egg lecithin.
  • the commercial material such as an oil or a lecithin, is fractionated and then the different lipid classes are admixed as explained in more detail in the examples below.
  • derivatives of lipids may also be used in combination with the above mentioned lipids.
  • polyethyleneglycol coupled to phospatidylethanolamine which has shown to prolong the circulation time of liposomes after injection in the blood stream.
  • palmitoylcarnitine which acts as an absorption enhancer for bioactive substances in the gut.
  • the bioactive substance is admixed to a selected lipid, followed by admixing of a lipid of a different polarity.
  • This polar/nonpolar alteration may be continued for as many cycles as necessary in the specific case, involving a range of lipids with different polarities.
  • the preferred way of incorporation of a bioactive substance into the BFM is to admix the bioactive substance to amphiphilic lipids in order to create a homogeneous formulation, where the amount of amphiphilic lipids generally is in the total range of 5-80 % (w/w).
  • amphiphilic lipid should be capable of spontaneous bilayer formation.
  • amphiphilic and polar lipid classes such as phosphatidylcholine, phosphatidylglycerol, phosphatidylinositol or phosphatidylserine or mixtures thereof.
  • the BFM should also contain one or more nonpolar lipid class.
  • nonpolar lipids are mono-, di- or triglycerols, cholesterol or its esters.
  • Endogenous water, ethanol or other solvents may be present in small amounts (not enough for Biosome formation) in the BFM if the bioactive substance needs such a solvate to be incorporated.
  • the design of the BFM includes not only the proper selection and/or combination of lipid classes, tailor-made for the solubilization of each bioactive substance, but also the proper selection of the distribution of fatty acids, i.e. the acyl groups attached to the utilized lipid classes. Variation of the acyl groups gives different physicochemical properties as will be seen in the examples below.
  • the rate by which the Biosomes are formed from the BFM in a given aqueous environment can be affected and controlled.
  • a second way of affecting and controlling the formation of Biosomes is by varying the structure, thus the fluidity, of the hydrocarbon chains in the nonpolar part of the BFM. This will affect the rate of interaction of the endogenous amphiphatic lipids and the exogenous aqueous medium.
  • lipid constituents for a specific BFM will be required in order to a) incorporate the bioactive compound in vitro and to b) release the bioactive component by Biosome formation in vivo .
  • the examples below will further illustrate the variation of the matrices by selection of lipids and combinations thereof without limiting the scope of invention.
  • the invention relates particularly to the design and behaviour of the BFM which is a new concept for drug delivery of bioactive materials.
  • the invention does not restrict the application of the BFM to any specific route of administration since the BFM will show potential applications for a variety of drug delivery forms such as absorbtion enhancement of oral, rectal, nasal, dermal formulations or controlled delivery via the parenteral route or locally, e.g. in the vagina or in wounds.
  • the present invention it is possible to incorporate both highly polar as well as nonpolar bioactive materials, in a flexible manner, into a lipid matrix structure by means of a combination of nonpolar lipids and amphiphatic compounds and that these drug containing BFM's form Biosomes, when the BFM's interact with water, thus generating a drug delivery system suitable for either an enhanced or controlled extravascular absorption or a controlled parenteral drug release combined with a biodegradation.
  • the present invention provides an improved and flexible drug delivery system applicable for various classes of bioactive materials.
  • vitamin B12 cyanocobolamine
  • BFM cyanocobolamine
  • parenteral drug delivery with controlled release has been found even for highly water-soluble bioactive material such as fragmentated heparin (Fragmin®) using the present invention.
  • highly water-soluble bioactive material such as fragmentated heparin (Fragmin®) using the present invention.
  • Fragmin® fragmentated heparin
  • Such a combination of a highly hydrophilic bioactive substance with a hydrophobic carrier has hitherto not yet been shown.
  • this new and unique property of the present lipid drug delivery carrier i.e. BFM
  • BFM lipid drug delivery carrier
  • Biosome Forming Matrices By incorporating bioactive materials according to the lipid matrix principle in this invention, referred to as Biosome Forming Matrices, the following advantages are obtained compared to conventional pharmaceutical dosage forms, or delivery systems:
  • This invention relates solely to the concept and design of the novel lipid matrices, the Biosome Forming Matrices, which show a unique formation of Biosomes in vivo after administration, and in which any suitable bioactive material can be incorporated, if needed for any particular reason, such as for improved bioavailability or for extended/controlled release purposes.
  • Lipid class composition (g) I II III Fatty acid composition of triacylglycerol (wt%) Phosphatidylcholine 0.50 Phosphatidylethanolamine 0.40 Phosphatidylinositol 0.23 Nonpolar lipids 0.12 Monoacylglycerol 0.63 Diacylglycerol 0.63 Triacylglycerol 2.50 8:0 caprylate 58.5 10:0 caprate 40.5 12:0 laurate 0.6 minors 0.4 Total 1.25 1.25 2.50 Total 100
  • Lipid class composition (g) I II III Fatty acid composition of triacylglycerol (wt%) Phosphatidylcholine 0.40 Phosphatidylethanolamine 0.35 Phosphatidylinositol 0.18 Phosphatidic acid 0.07 Nonpolar lipids 0.25 Monoacylglycerol 0.63 Diacylglycerol 0.63 Triacylglycerol 2.50 8:0 caprylate 58.5 10:0 caprate 40.5 12:0 laurate 0.6 minors 0.4 Total 1.25 1.25 2.50 Total 100
  • Lipid class composition (g) I II III Fatty acid composition of triacylglycerol (wt%) Phosphatidylcholine 0.50 Phosphatidylethanolamine 0.40 Phosphatidylinositol 0.23 Nonpolar lipids 0.12 Monoacylglycerol 0.63 Diacylglycerol 0.63 Triacylglycerol 2.50 16:0 palmitate 10.0 18:0 sterarate 2.8 18:1 oleate 20.6 18:2 linoleate 58.9 18:3 linolenate 6.7 minors 1.0 Total 1.25 1.25 2.50 Total 100
  • Lipid class composition (g) I II III Fatty acid composition of triacylglycerol (wt%) Phosphatidylcholine 0.40 Phosphatidylethanolamine 0.35 Phosphatidylinositol 0.18 Phosphatidic acid 0.07 Nonpolar lipids 0.25 Monoacylglycerol 0.63 Diacylglycerol 0.63 Triacylglycerol 2.50 16:0 palmitate 10.0 18:0 sterarate 2.8 18:1 oleate 20.6 18:2 linoleate 58.9 18:3 linolenate 6.7 minors 1.0 Total 1.25 1.25 2.50 Total 100
  • Lipid class composition I II Phosphatidylcholine 0.40 Phosphatidylethanolamine 0.35 Phosphatidylinositol 0.18 Phosphatidic acid 0.07 Nonpolar lipids 0.25 Monoacylglycerol 0.63 Diacylglycerol 0.63 Triacylglycerol Total 1.25 1.25
  • Lipid class composition (g) I II III Phosphatidylcholine 0.40 Phosphatidylethanolamine 0.35 Phosphatidylinositol 0.18 Phosphatidic acid 0.07 Nonpolar lipids 0.25 Monoacylglycerol 0.63 Diacylglycerol 0.63 Triacylglycerol 0.16 Total 1.25 1.25 0.16
  • Lipid class composition (g) I II III Fatty acid composition of triacylglycerol (wt%) Phosphatidylcholine 1.25 Monoacylglycerol 0.63 Diacylglycerol 0.63 Triacylglycerol 2.50 8:0 caprylate 58.5 10:0 caprate 40.5 12:0 laurate 0.6 minors 0.4 Total 1.25 1.25 2.50 Total 100
  • Lipid class composition (g) I II III Fatty acid composition of triacylglycerol (wt%) Phosphatidylcholine 1.25 Monoacylglycerol 0.63 Diacylglycerol 0.63 Triacylglycerol 2.50 16:0 palmitate 10.0 18:0 sterarate 2.8 18:1 oleate 20.6 18:2 linoleate 58.9 18:3 linolenate 6.7 minors 1.0 Total 1.25 1.25 2.50 Total 100
  • cyanocobalamin (B12) is added to 2.50 g of a monoglyceride (II) and the mixture is gently stirred for 3 h at 60 °C.
  • 2.50 g phosphatidylcholine from soybean (I) is added and the stirring continues for 6 h at 60 °C.
  • 5.00 g of a triglyceride (III) is added and the total mixture is stirred for another hour at the elevated temperature.
  • Lipid class composition (g) I II III Fatty acid composition of triacylglycerol (wt%) Phosphatidylcholine 2.50 Monoacylglycerol 2.50 Triacylglycerol 5.00 8:0 caprylate 58.5 10:0 caprate 40.5 12:0 laurate 0.6 minors 0.4 Total 2.50 2.50 5.00 Total 100
  • cyanocobalamin (B12) is added to 2.50 g of a monoglyceride (II) and the mixture is gently stirred for 3 h at 60 °C.
  • 2.50 g phosphatidylcholine from soybean (I) is added and the stirring continues for 6 h at 60 °C.
  • 5.00 g of a triglyceride (III) is added and the total mixture is stirred for another hour at the elevated temperature.
  • Lipid class composition (g) I II III Fatty acid composition of triacylglycerol (wt%) Phosphatidylcholine 2.50 Monoacylglycerol 2.50 Triacylglycerol 5.00 16:0 palmitate 10.0 18:0 sterarate 2.8 18:1 oleate 20.6 18:2 linoleate 58.9 18:3 linolenate 6.7 minors 1.0 Total 2.50 2.50 5.00 Total 100
  • worm-like textures are formed in the lipid phase, i.e. the Biosome Forming Matrix, which moves towards the interface between water and lipid.
  • these textures are rapidly transformed by a 'budding' process into spherical lipid vesicles, denoted as Biosomes in this invention.
  • Example 9 Initially, smaller Biosomes are spontaneously formed for Example 9 compared to Example 10 as evident from Table III. Furthermore, for the smaller Biosome forming matrices a more rapid drug release can be seen, cf. Table II. Another interesting phenomenon can be seen in Table III in terms of the time for the formation of smaller Biosomes. A longer lag time for this process was found for Example 10 compared to Example 9 which demonstrated the possibility of controlling this process by means of lipid composition in the BFM's.
  • Lipid class composition I II Phosphatidylcholine 2.50 Monoacylglycerol 7.50 Total 2.50 7.50
  • Example 15 was also administered in a rabbit by subcutaneous injection. Blood samples were collected and the plasma concentration of Fragmin® was analyzed as a function of time. The results are shown in Table V. Table V Time (h) Fragmin® plasma concentration (IU/ml) 0 0 1.0 0 2.0 0 2.5 0.051 3.0 0.100 3.5 0.110 4.0 0.127 4.5 0.130 5.0 0.122 5.5 0.126 6.0 0.133 7.0 0.126
  • Examples 16-23 show various formulations based on the present invention demonstrating the flexibility of said invention.
  • the examples show that it is possible to incorporate both highly complex molecules such as vitamin B12 as well as low molecular weight compound, e.g. buspirone and high molecular weight molecules, e.g. fragmentated heparin (Fragmin®) where each bioactive compound possesses different physicochemical properties.
  • highly complex molecules such as vitamin B12
  • low molecular weight compound e.g. buspirone
  • high molecular weight molecules e.g. fragmentated heparin (Fragmin®) where each bioactive compound possesses different physicochemical properties.
  • Lipid class composition (g) I II III Fatty acid composition of triacylglycerol (wt%) Phosphatidylcholine 12.50 Monoacylglycerol 12.50 Triacylglycerol 25.00 8:0 caprylate 58.5 10:0 caprate 40.5 12:0 laurate 0.6 minors 0.4 Total 12.50 12.50 25.00 Total 100
  • Lipid class composition (g) I II III Fatty acid composition of triacylglycerol (wt%) Phosphatidylcholine 12.50 Monoacylglycerol 12.50 Triacylglycerol 25.00 16:0 palmitate 10.0 18:0 sterarate 2.8 18:1 oleate 20.6 18:2 linoleate 58.9 18:3 linolenate 6.7 minors 1.0 Total 12.50 12.50 25.00 Total 100
  • 15 mg cyanohydroxycobalamin acetate is added to 1.25 g of a glyceride mixture (II) and gently stirred at 60 °C for 3 h.
  • 1.25 g phosphatidylcholine from soybean (I) is added and the stirring continues for 6 h at 60 °C.
  • 2.50 g of a triglyceride (III) is added and the total mixture is stirred for another hour at the elevated temperature.
  • Lipid class composition (g) I II III Fatty acid composition of triacylglycerol (wt%) Phosphatidylcholine 1.25 Monoacylglycerol 0.63 Diacylglycerol 0.63 Triacylglycerol 2.50 8:0 caprylate 58.5 10:0 caprate 40.5 12:0 laurate 0.6 minors 0.4 Total 1.25 1.25 2.50 Total 100
  • 15 mg cyanohydroxycobalamin acetate is added to 1.25 g of a glyceride mixture (II) and gently stirred at 60 °C for 3 h.
  • 1.25 g phosphatidylcholine from soybean (I) is added and the stirring continues for 6 h at 60 °C.
  • 2.50 g of a triglyceride (III) is added and the total mixture is stirred for another hour at the elevated temperature.
  • Lipid class composition (g) I II III Fatty acid composition of triacylglycerol (wt%) Phosphatidylcholine 1.25 Monoacylglycerol 0.63 Diacylglycerol 0.63 Triacylglycerol 2.50 16:0 palmitate 10.0 18:0 sterarate 2.8 18:1 oleate 20.6 18:2 linoleate 58.9 18:3 linolenate 6.7 minors 1.0 Total 1.25 1.25 2.50 Total 100
  • Lipid class composition I II Phosphatidylcholine 2.50 Monoacylglycerol 7.50 Total 2.50 7.50
  • buspirone hydrochloride 10 mg buspirone hydrochloride is added to 50 mg of a monoglyceride (II) and the mixture is gently stirred for 1 h at 60 °C.
  • 200 mg of a diglyceride (III) and 250 mg phosphatidylcholine from soybean (I) is added and the stirring continues for 3 h at 60 °C.
  • 500 mg of a triglyceride (IV) is added and the total mixture is stirred for another 10 min at the elevated temperature.
  • Lipid class composition (mg) I II III IV Fatty acid composition of triacylglycerol (wt%) Phosphatidylcholine 250 Monoacylglycerol 50 Diacylglycerol 200 Triacylglycerol 500 8:0 caprylate 58.5 10:0 caprate 40.5 12:0 laurate 0.6 minors 0.4 Total 250 50 200 500 Total 100

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Birds (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Colloid Chemistry (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Saccharide Compounds (AREA)
  • Fertilizers (AREA)
EP91919389A 1990-09-28 1991-09-24 Lipid formulation system Expired - Lifetime EP0514506B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9003100 1990-09-28
SE9003100A SE9003100D0 (sv) 1990-09-28 1990-09-28 Lipid formulation system
PCT/SE1991/000639 WO1992005771A1 (en) 1990-09-28 1991-09-24 Lipid formulation system

Publications (2)

Publication Number Publication Date
EP0514506A1 EP0514506A1 (en) 1992-11-25
EP0514506B1 true EP0514506B1 (en) 1996-05-08

Family

ID=20380490

Family Applications (1)

Application Number Title Priority Date Filing Date
EP91919389A Expired - Lifetime EP0514506B1 (en) 1990-09-28 1991-09-24 Lipid formulation system

Country Status (15)

Country Link
EP (1) EP0514506B1 (ja)
JP (1) JP2855594B2 (ja)
AT (1) ATE137667T1 (ja)
AU (1) AU645143B2 (ja)
CA (1) CA2069760C (ja)
DE (1) DE69119400T2 (ja)
DK (1) DK0514506T3 (ja)
ES (1) ES2088024T3 (ja)
FI (1) FI107696B (ja)
GR (1) GR3020674T3 (ja)
IE (1) IE62194B1 (ja)
NO (1) NO304729B1 (ja)
PT (1) PT99113B (ja)
SE (1) SE9003100D0 (ja)
WO (1) WO1992005771A1 (ja)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260065A (en) * 1991-09-17 1993-11-09 Micro Vesicular Systems, Inc. Blended lipid vesicles
SE9200952D0 (sv) * 1992-03-27 1992-03-27 Kabi Pharmacia Ab Pharmaceutical carrier system containing defined lipids
SE9200951D0 (sv) * 1992-03-27 1992-03-27 Kabi Pharmacia Ab Pharmaceutical composition containing a defined lipid system
ES2158084T3 (es) * 1994-02-04 2001-09-01 Lipocore Holding Ab Preparaciones vehiculo lipofilicas.
DE4447287C1 (de) * 1994-12-30 1996-11-07 Cevc Gregor Präparat zum Wirkstofftransport durch Barrieren
SE9703691D0 (sv) 1997-10-10 1997-10-10 Astra Ab Pharmaceutical compositions
GB2344520A (en) * 1998-12-08 2000-06-14 Phares Pharm Res Nv Pharmaceutical carriers comprising lipids and polymers
ES2226203T3 (es) 1998-12-23 2005-03-16 Idea Ag Formulacion mejorada para aplicacion topica no invasiva.
SE0000730D0 (sv) * 2000-03-06 2000-03-06 Scotia Holdings Plc Lipid carrier
SE0200475D0 (sv) * 2002-02-15 2002-02-15 Ltp Lipid Technologies Provide Oral farmaceutisk beredning
SE0201922D0 (sv) * 2002-06-20 2002-06-20 Ltp Lipid Technologies Provide Koagulationshindrande komposition (Anticoagulant Composition)
FR2868704B1 (fr) * 2004-04-07 2007-09-14 Ethypharm Sa Utilisation de lipides pour ameliorer la biodisponibilite de principes actifs proteiques en formulations injectables sous cutanees ou intra-musculaires
US20050232981A1 (en) 2004-04-15 2005-10-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
US20090041829A1 (en) * 2005-04-28 2009-02-12 Galenica Technology Ab Pharmaceutical dosage forms comprising a lipid phase
PT1933809E (pt) * 2005-10-11 2012-04-26 Yissum Res Dev Co Composições para administração por via nasal
BRPI0918652B1 (pt) 2008-09-17 2021-10-19 Chiasma, Inc. Composição farmacêutica compreendendo um meio hidrofóbico e uma forma sólida que compreende polipeptídeo e sal de ácido graxo de cadeia média, processo de produção da mesma e forma de dosagem oral
CN101926757B (zh) * 2010-09-01 2013-01-02 北京大学 一种难溶性药物的液体组合物及其制备方法
US10238709B2 (en) 2015-02-03 2019-03-26 Chiasma, Inc. Method of treating diseases
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
CN117580560A (zh) * 2021-05-03 2024-02-20 Mcal治疗公司 微粉化脂质

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT8219012A0 (it) * 1982-01-06 1982-01-06 Ausonia Farma Srl Metodo per la somministrazione orale di sostanze sotto forma di liposomi, e relative formulazioni farmaceutiche.
GB8613811D0 (en) * 1986-06-06 1986-07-09 Phares Pharm Res Nv Composition & method
EP0158441B2 (en) * 1984-03-08 2001-04-04 Phares Pharmaceutical Research N.V. Liposome-forming composition
US4610868A (en) * 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
SE8603812D0 (sv) * 1986-09-12 1986-09-12 Draco Ab Administration of liposomes to mammals
EP0280394B1 (en) * 1987-01-27 1994-12-14 Vestar, Inc. Phospholipid delivery vehicle for aqueous-insoluble active ingredients

Also Published As

Publication number Publication date
AU8710591A (en) 1992-04-28
GR3020674T3 (en) 1996-10-31
PT99113A (pt) 1992-08-31
FI922452A (fi) 1992-05-27
FI922452A0 (fi) 1992-05-27
ATE137667T1 (de) 1996-05-15
DE69119400T2 (de) 1996-12-05
IE913246A1 (en) 1992-04-08
IE62194B1 (en) 1994-12-28
DK0514506T3 (da) 1996-08-12
ES2088024T3 (es) 1996-08-01
PT99113B (pt) 1999-02-26
AU645143B2 (en) 1994-01-06
JPH05503711A (ja) 1993-06-17
WO1992005771A1 (en) 1992-04-16
CA2069760A1 (en) 1992-03-29
JP2855594B2 (ja) 1999-02-10
CA2069760C (en) 1998-02-10
FI107696B (fi) 2001-09-28
NO922084L (no) 1992-05-26
DE69119400D1 (de) 1996-06-13
NO922084D0 (no) 1992-05-26
SE9003100D0 (sv) 1990-09-28
NO304729B1 (no) 1999-02-08
EP0514506A1 (en) 1992-11-25

Similar Documents

Publication Publication Date Title
US5665379A (en) Lipid particle forming matrix, preparation and use thereof
EP0514506B1 (en) Lipid formulation system
JP3203359B2 (ja) 親油性担体製剤
CA2294337C (en) Preparation of pharmaceutical compositions
KR102037354B1 (ko) 생리활성물질 봉입을 위한 나노지질전달체 및 이의 제조방법
JPH09508414A (ja) 二重層製剤
JPS60155109A (ja) リポソ−ム製剤
JP2003513019A (ja) トコール可溶性治療剤の組成物
DE69426570T2 (de) Mizelleförmige feinteilige pharmazeutische zusammensetzungen
CA2268670A1 (en) Preparation for transporting active ingredients through barriers
Patel et al. Niosome: a vesicular drug delivery tool
JPH07108166A (ja) リポソーム
KR102190935B1 (ko) 생리활성물질 봉입을 위한 나노지질전달체 및 이의 제조방법
Cai et al. Lipid nanoparticle steric stabilization roadmap
CA2248351A1 (en) Method for solubilising hydrophylic materials (e.g. proteins) in a hydrophobic solvent
KR20190050697A (ko) 혼합 세라마이드를 포함하는 화장료 조성물 제조방법 및 상기 방법에 의해 제조한 화장료 조성물
KR20220131805A (ko) 매스틱검 또는 감마오리자놀로 제조한 지질나노입자 조성물
RU2127124C1 (ru) Препараты липофильных носителей
KR100690103B1 (ko) 파이토스핑고신 리포좀 조성물의 제조방법
Verma et al. Liposomes as carrier systems

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19920508

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19950131

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PHARMACIA AB (REG.NUMBER 556131-9608)

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

REF Corresponds to:

Ref document number: 137667

Country of ref document: AT

Date of ref document: 19960515

Kind code of ref document: T

REF Corresponds to:

Ref document number: 69119400

Country of ref document: DE

Date of ref document: 19960613

REG Reference to a national code

Ref country code: ES

Ref legal event code: BA2A

Ref document number: 2088024

Country of ref document: ES

Kind code of ref document: T3

ITF It: translation for a ep patent filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2088024

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: DIETLIN & CIE S.A.

REG Reference to a national code

Ref country code: GR

Ref legal event code: FG4A

Free format text: 3020674

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

REG Reference to a national code

Ref country code: FR

Ref legal event code: CD

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20050701

Year of fee payment: 15

Ref country code: AT

Payment date: 20050701

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20050726

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20050808

Year of fee payment: 15

Ref country code: NL

Payment date: 20050808

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20050809

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20050902

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20050905

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20050912

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20050927

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20050930

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20051006

Year of fee payment: 15

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060924

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060925

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060930

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060930

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060930

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20060930

Year of fee payment: 16

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061002

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070401

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070403

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

EUG Se: european patent has lapsed
GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20060924

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20070401

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20070531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060924

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20060925

BERE Be: lapsed

Owner name: *PHARMACIA & UPJOHN A.B.

Effective date: 20060930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060925

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061002

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060924

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070404

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070924